Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project.

[1]  A. Addeo,et al.  Targeted Therapies in Early Stage NSCLC: Hype or Hope? , 2020, International journal of molecular sciences.

[2]  A. Drilon,et al.  KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. , 2020, Cancer treatment reviews.

[3]  J. Lunceford,et al.  LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .

[4]  Jie Wu,et al.  The emerging treatment landscape of targeted therapy in non-small-cell lung cancer , 2019, Signal Transduction and Targeted Therapy.

[5]  A. Addeo,et al.  The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience , 2019, Cancer Genomics & Proteomics.

[6]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[7]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[8]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[9]  A. Addeo,et al.  Tumor Mutation Burden-From Hopes to Doubts. , 2019, JAMA oncology.

[10]  A. Warth,et al.  A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. , 2019, Lung cancer.

[11]  A. Warth,et al.  Computer‐Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[13]  A. Shaw,et al.  Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[15]  Ying Cheng,et al.  Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer , 2018 .

[16]  A. Warth,et al.  Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. , 2017, Lung cancer.

[17]  Jian Su,et al.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[18]  M. Schaeffer,et al.  Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery , 2016, British Journal of Cancer.

[19]  L. Seymour,et al.  Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[21]  M. Ladanyi,et al.  Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  A. Marchetti,et al.  Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  C. Dooms,et al.  Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Warth,et al.  Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .